How to invest in Health & Life Sciences – Practical insights and examples

Thursday 19 May 2022, 8:30–13:00 (EEST)
Team Finland House, Porkkalankatu 1, Helsinki

Have you ever been curious about Health and Life Sciences as an investment opportunity? Now is your chance: Welcome to the How to invest in Health & Life Sciences event in Helsinki on 19 May.

The specialised investors from the Nordics and beyond will guide you through what should be taken into consideration when investing in health & life science startups and what the industry’s investment landscape looks like.

During the half-day event you’ll learn:

What is the investment roadmap and horizon for Health & Life Science investments?
How do research-based innovations play out as investment opportunities?
What are the growth drivers for Health & Life Sciences?
What is the current status of Health & Life Science in Finland and Europe?
How to build a successful Health & Life Science fund?

Thank you for attending!

Please find all the presentations here:

Harry Brade / Business Finland Venture Capital 190522
Pekka Simula & Milla Koistinaho / Innovestor Life Science Fund 190522
Carl Kilander / HealthCap 190522
Georgina Askeland / Hadean Ventures 190522
Joni Karsikas / Tesi 190522

Event details

When: Thursday 19 May,
8.30–13.00 (EEST), including morning coffee and lunch

Where: Team Finland House, Porkkalankatu 1, Helsinki (Business Finland auditorium, 1st floor)

Why: You’ll learn everything you need to when investing in Health & Life Sciences from seasoned international GP’s and LP’s.

For whom: Health & Life Sciences entrepreneurs, angel investors, institutional investors & family offices, tech transfer specialists, experts in the Health & Life Sciences sector, and anyone interested in investing in Health & Life Sciences and eager to network with like-minded.

The event is free of charge but registration is required. Welcome!

Event agenda, Thursday 19 May 2022

8:15-9:00

Morning coffee and networking
9:00-10:30
Session 1: Investing in Health tech and Life Science companies – What should be taken into consideration from investor point of view?
Topics:
- Diversity in the health and life science sector?
- What is the investment roadmap and horizon for Health & Life Science investments?
- How do research-based innovations play out as investment opportunities?
- What are the growth drivers for Health & Life Sciences?
- What is the current status of Health & Life Science in Finland and Europe?
Speakers:
- Harry Brade, Chairman of the Board, Business Finland Venture Capital
- Carl Kilander, Partner, HealthCap
- Georgina Askeland, Investment Associate, Hadean Ventures
- Milla Koistinaho, General Partner, Innovestor Life Science Fund
- Pekka Simula, General Partner, Innovestor Life Science Fund
- Joni Karsikas, Investment Director, Tesi (Finnish Industry Investment Ltd)
10:30-11:00

Coffee break & Networking
11:00-12:00
Session 2: Panel discussion – What makes a good fund and how to build one?
Panelists:
- Carl Kilander, Partner, HealthCap
- Georgina Askeland, Investment Associate, Hadean Ventures
- Petri Serenius, Investment Director, Business Finland Venture Capital
- Aki Koivistoinen, StartUp Health Ambassador, Europe & Israel
- Karita Meling, Head of Private Equity, Elo Mutual Pension Insurance Company
Q&A session with the panelists
12:00-13:00

Networking lunch

Organisers and contact info

Sampo Sammalisto
Head of Personalized Health Finland Program
sampo.sammalisto
@businessfinland.fi
+358 50 584 1100

Asseri Lehtiniemi
Investment Manager, Business Finland Venture Capital
asseri.lehtiniemi
@businessfinland.vc
+358 44 536 1080

Lauri Kuronen
Senior Business Advisor, Health Capital Helsinki
lauri.kuronen
@healthcapitalhelsinki.fi
+358 400 244 209

Saara Hassinen
CEO, Healthtech Finland
saara.hassinen
@teknologiateollisuus.fi
+358 40 531 1661

Recent news

From Health Capital Helsinki

Moncyte targets optimal cholesterol-lowering therapy

Aug 17, 2022

Moncyte R&D team from University of Helsinki has developed a unique solution that sheds light on why some people respond differently to cholesterol-lowering drugs.